Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Candel TherapeuticsCADL +7.38%30 Market Cap is $745.16 Mil as of Jul. 18, 2026. GuruFocus rates CADL with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 1,423 Biotechnology companies, Candel Therapeutics ranks better than 75.26% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Candel Therapeutics's share price for the quarter that ended in Mar. 2026 was $4.9. Candel Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 73.26 Mil. Therefore, Candel Therapeutics's market cap for the quarter that ended in Mar. 2026 was $358.96 Mil.
Candel Therapeutics's quarterly market cap
increased
from Sep. 2025 ($279.97 Mil) to Dec. 2025 ($310.17 Mil) and
increased
from Dec. 2025 ($310.17 Mil) to Mar. 2026 ($358.96 Mil).
Candel Therapeutics's annual market cap
increased
from Dec. 2023 ($42.76 Mil) to Dec. 2024 ($406.31 Mil) but then
declined
from Dec. 2024 ($406.31 Mil) to Dec. 2025 ($310.17 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Candel Therapeutics's Enterprise Value for Today is $599.60 Mil.
Candel Therapeutics (NAS:CADL) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Candel Therapeutics Market Cap Related Terms
Candel Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Candel Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Candel Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Candel Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Candel Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Candel Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Candel Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Candel Therapeutics (CADL) has a Market Cap of $745.16 Mil as of Jul. 18, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Candel Therapeutics and its competitors. According to the industry distribution chart, Candel Therapeutics ranks #352 out of 1423 companies in the Biotechnology industry, placing it in the top 24.7%.
Is Candel Therapeutics' Market Cap too high?
Candel Therapeutics' current Market Cap is $745.16 Mil. The Biotechnology industry median Market Cap is 113.78. Candel Therapeutics' value of $745.16 Mil is 554.9% above this industry median. Based on the distribution chart, Candel Therapeutics ranks #352 out of 1423 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Candel Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Candel Therapeutics' Market Cap compare to AURA and RIGL?
According to the Biotechnology industry distribution chart, Candel Therapeutics ranks #352 out of 1423 companies for Market Cap. This places Candel Therapeutics in the top 25% of its industry — outperforming the majority of peers. The industry median Market Cap is 113.78. Candel Therapeutics' value of $745.16 Mil is 554.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.78, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Candel Therapeutics's current Market Cap of $745.16 Mil is 554.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Candel Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 113.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Candel Therapeutics's current Market Cap is $745.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Candel Therapeutics stock overvalued right now?
Candel Therapeutics (CADL) has a current Market Cap of $745.16 Mil. The current Market Cap is $745.16 Mil and 554.9% above the Biotechnology industry median of 113.78. Candel Therapeutics' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Candel Therapeutics (CADL), the current Market Cap is $745.16 Mil as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
30GF Score
Get the complete analysis for CADL
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CADL has been successfully added to your 
